Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
National Institutes of Health · Opportunity PAR-25-450
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
About this opportunity
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success. This could be through the development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | National Institutes of Health | November 23, 2026 | $375k | |
| BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) | National Institutes of Health | June 15, 2027 | — | Nonprofits |
| Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2027 | — | Nonprofits |
| Advancement and Innovation in Measurement of Language Development and Predictors (R21 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2027 | — | Nonprofits |